Aquestive Therapeutics (NASDAQ:AQST) will release its earnings data after the market closes on Tuesday, November 6th. Analysts expect Aquestive Therapeutics to post earnings of ($0.49) per share for the quarter.
Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, September 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($1.66). The company had revenue of $13.93 million during the quarter. On average, analysts expect Aquestive Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:AQST opened at $17.33 on Friday. Aquestive Therapeutics has a 12-month low of $13.61 and a 12-month high of $20.70.
Several research firms recently issued reports on AQST. Wedbush set a $34.00 target price on Aquestive Therapeutics and gave the stock a “buy” rating in a research report on Thursday, October 25th. Royal Bank of Canada began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating and a $23.00 target price for the company. JMP Securities began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating and a $29.00 target price for the company. Finally, BMO Capital Markets began coverage on Aquestive Therapeutics in a research report on Monday, August 20th. They set an “outperform” rating for the company.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Recommended Story: Why do companies engage in swaps?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.